A5064572030- Diabetes Treatment and Management
- Regulation of Appetite and Obesity
- Adenosine and Purinergic Signaling
- Pancreatic function and diabetes
- Platelet Disorders and Treatments
- Cardiovascular Issues in Pregnancy
- ATP Synthase and ATPases Research
- Estrogen and related hormone effects
- Nitric Oxide and Endothelin Effects
- Chronic Lymphocytic Leukemia Research
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Eicosanoids and Hypertension Pharmacology
- Diet and metabolism studies
- Biochemical Analysis and Sensing Techniques
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Porphyrin and Phthalocyanine Chemistry
- Phytochemistry and Biological Activities
- Natural product bioactivities and synthesis
- Pregnancy and Medication Impact
- Genomic variations and chromosomal abnormalities
- Pharmacological Effects and Toxicity Studies
- Protein Tyrosine Phosphatases
- Multicomponent Synthesis of Heterocycles
- Blood properties and coagulation
Inserm
2010-2024
Université Toulouse III - Paul Sabatier
2008-2024
Institut des Maladies Métaboliques et Cardiovasculaires
2007-2024
Université de Toulouse
2007-2022
Centre de Physiopathologie de Toulouse-Purpan
2022
Centre Hospitalier Universitaire de Toulouse
2008-2018
Pharmacochimie et Pharmacologie pour le Développement
2008-2014
Hôpital Rangueil
2011-2014
Observatoire Midi-Pyrénées
2003-2006
Inhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode action related to the stabilization active forms DPP-4-sensitive hormones such as incretins that enhance glucose-induced insulin secretion. However, DPP-4 enzyme is highly expressed on surface intestinal epithelial cells; hence, role vs. systemic remains unclear. To analyze mechanisms which inhibitor sitagliptin regulates glycemia in mice, we administered low oral doses selectively reduced...
To ascertain the importance and mechanisms underlying role of brain glucagon-like peptide (GLP)-1 in control metabolic cardiovascular function. GLP-1 is a gut hormone secreted response to oral glucose absorption that regulates metabolism also produced brain, where its contribution central regulation homeostasis remains incompletely understood.Awake free-moving mice were infused with receptor agonist exendin-4 (Ex4) into lateral ventricle basal state or during hyperinsulinemic...
Glucagon-like peptide-1 (GLP-1) is a peptide released by the intestine and brain. We previously demonstrated that brain GLP-1 increases glucose-dependent hyperinsulinemia insulin resistance. These two features are major characteristics of onset type 2 diabetes. Therefore, we investigated whether blocking signaling would prevent high-fat diet (HFD)-induced diabetes in mouse. Our data show 1-month chronic blockage exendin-9 (Ex9), totally prevented resistance HFD mice. Furthermore, food intake...
OBJECTIVE—Central neural insulin regulates glucose homeostasis, but less is known about its cardiovascular effects. Endothelial nitric oxide synthase (eNOS)-derived (NO) represents a molecular link between metabolic and disease. Its role in the central nervous system remains to be determined. We studied effects of infusion on femoral arterial blood flow heart rate normal chow–fed, high-fat diet–fed diabetic, eNOS-null mice. RESEARCH DESIGN AND METHODS —We recorded (ultrasonic probe) during...
Glucagon-like peptide 1 (GLP-1) is a gut-brain hormone that regulates food intake, energy metabolism, and cardiovascular functions. In the brain, through currently unknown molecular mechanism, it simultaneously reduces femoral artery blood flow muscle glucose uptake. By analogy to pancreatic β-cells where GLP-1 activates protein kinase C (PKC) stimulate insulin secretion, we postulated PKC enzymes would be targets of brain signaling regulate metabolic vascular function. We used both genetic...
Objective— PI3Kα (phosphoinositide 3-kinase alpha) is a therapeutic target in oncology, but its role platelets and thrombosis remains ill characterized. In this study, we have analyzed the of vitro, ex vivo, vivo 2 models arterial thrombosis. Approach Results— Using mice selectively deficient p110α megakaryocyte lineage isoform-selective inhibitors, confirm that not mandatory participates to thrombus growth over collagen matrix at shear rate. Our data uncover for low-level activation GP...
High-density lipoproteins (HDL) exert multiple cardioprotective functions on the arterial wall, including promotion of endothelial cell survival and proliferation. Among mechanism contributing to protection, it has been reported that apolipoprotein A-I (apoA-I), major protein in HDL, binds activates ecto-F1-ATPase receptor. This generates extracellular ADP, which turn promotes survival. In this study we aimed further investigate signaling pathway involved downstream apoA-I-induced...
The contribution of apolipoprotein A1 (APOA1), the major high-density lipoprotein (HDL), to endothelium-dependent vasodilatation is unclear, and there little information regarding endothelial receptors involved in this effect. Ecto-F1 -ATPase a receptor for APOA1, its activity cells coupled adenosine diphosphate (ADP)-sensitive P2Y (P2Y ADP receptors). APOA1-mediated cell proliferation HDL transcytosis. Here, we investigated effect lipid-free APOA1 involvement ecto-F1 on nitric oxide (NO)...
Excessive lipolysis in white adipose tissue (WAT) leads to insulin resistance (IR) and ectopic fat accumulation insulin-sensitive tissues. However, the impact of Gi-coupled receptors restraining adipocyte through inhibition cAMP production remained poorly elucidated. Given that P2Y13 receptor (P2Y13-R) is a purinergic expressed WAT, we investigated its role effect on IR metabolic dysfunction-associated steatotic liver disease (MASLD). In humans, mRNA expression P2Y13-R WAT was negatively...
We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via hematopoietic estrogen receptor alpha (ERα), independently of ERβ. Here, we have explored respective roles membrane vs nuclear actions ERα this process, using: 1) selective activator ERα: dendrimer conjugate, 2) mouse models with mutations ERα. The targeting activation function 2 provides a model...
Abstract Atherosclerosis is a chronic inflammatory disease of the vascular wall, in large part initiated by accumulation cholesterol‐laden macrophages (foam cells) walls and medium arteries, without adequate removal cholesterol high‐density lipoproteins. These lipid deposits promote an response formation atherosclerotic plaques that damage wall can be further complicated plaque disruption thrombosis. The molecular mechanisms controlling atherosclerosis are sensitive to lipids their...